Skip to content
Screener

Novanta NOVT Automation Enabling Technologies — Research And Development Expense

Similar metrics at other companies

Chemours logo
CCTitanium Technologies — Research And Development Expense
$7M-12.5%
Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
Bruker logo
BRKREnergy And Supercon Technologies — Research And Development Expense
$1M-9.1%
Viasat logo
VSATDefense And Advanced Technologies — Research And Development Expense
$17.1M+14.0%
Solid Biosciences Inc. logo
SLDBInternal Research And Development Expense — Research And Development Expense
$9.06M+33.9%
Disc Medicine logo
IRONInternal Research And Development — Research And Development Expense
$11.31M+67.6%

Other financials

Income statement

See full
Revenue$265.8M+10.3%
Gross profit$120.9M+13.3%
Operating income$18.1M+21.1%
Net income$12.5M+179%
EPS (diluted)$0.30+150%

Balance sheet

See full
Cash & equivalents$718.7M+554%
Total debt$285.6M-44.5%
Total equity$1.6B+102%
Total assets$2.1B+41.6%

Cash flow

See full
Operating cash flow$64.9M+331%
CapEx$7.5M+120%
Free cash flow$57.5M+392%

Valuation

See full
Market cap$5.82B+42.2%
Enterprise value$5.38B+19.7%
P/E94.2×+27.5×
P/S5.7×+1.4×

Profitability

See full
Gross margin44.5%-0.2pp
Operating margin9%-2.2pp
Net margin6%-0.4pp
FCF margin11.1%-1.2pp

Returns & leverage

See full
Return on equity5.1%-3.1pp
Debt / equity0.2×-0.5×
Current ratio4.6×+2.0×

Where this comes from

Reported directly by Novanta in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Novanta’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335404
Line itemThree Months Ended July 3, 2026 / Automation Enabling TechnologiesThree Months Ended July 3, 2026 / Medical SolutionsThree Months Ended July 3, 2026 / TotalSix Months Ended July 3, 2026 / Automation Enabling TechnologiesSix Months Ended July 3, 2026 / Medical SolutionsSix Months Ended July 3, 2026 / Total
Cost of revenue63,41976,714130,707148,443
Amortization of purchased intangible assets1,2002,5552,4005,114
Segment gross profit71,59650,323121,919134,352102,498236,850
Research and development and engineering9,49614,66718,52828,915
Selling, general and administrative20,78416,58540,67332,891
Amortization of purchased intangible assets2,7043,7114,8237,366
Restructuring, acquisition, and related costs2,0201,7532,5832,993
Segment operating income36,59213,60750,19967,74530,33398,078

Item 1. Financial Statements

FAQ

What is Novanta's automation enabling technologies — research and development expense?
Novanta (NOVT) reported automation enabling technologies — research and development expense of $9.5M in Q2 2026.
How has Novanta's automation enabling technologies — research and development expense changed year-over-year?
Novanta's automation enabling technologies — research and development expense increased by 2.4% year-over-year, from $9.27M to $9.5M.
What is the long-term trend for Novanta's automation enabling technologies — research and development expense?
Over 3 years (2022 to 2025), Novanta's automation enabling technologies — research and development expense has grown at a -6.0% compound annual growth rate (CAGR), from $45.44M to $37.8M.
What does automation enabling technologies — research and development expense mean?
Costs incurred by the Automation Enabling Technologies segment for the discovery and development of new products, technologies, or processes. This investment is critical for maintaining long-term competitive advantage and innovation within the automation sector.

Ask your AI about Novanta's automation enabling technologies — research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude